Skip to main content
Clinical Trials/CTRI/2020/03/024293
CTRI/2020/03/024293Completed未知

Impact of MTHFR, MS and CBS genes polymorphisms and vitamin B6, B9 & B12 supplementations on hyperhomocysteinemia among Ischemic stroke patients.

All India Institue of Medical sciences AIIMS Rishikesh0 sites90 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
90

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1Patients who will be having first-ever Ischemic stroke within 72 hours diagnosed by Neurologist with help of CT/MRI report.
  • 2Patients who will be having hyperhomocysteinemi at baseline.
  • 3Patients who willbe having normal renal function.

Exclusion Criteria

  • 1 Patients who will be suffering from disease Migraine, Alzheimer dementia, Parkinsonââ?¬•s disease are excluded from the study.
  • 2Patients with recurrent Ischemic stroke and having significant disabilities are excluded from the study.
  • 3Patients who having history of vitamin B6, B12, Folic acid supplementations, sex hormonal preparations like androgens intake and treated for depression, dementia, 6 months prior to attack of Ischemic stroke are excluded from the study.
  • 4Patients who having hypothyroidism, psoriasis, malignancies, rheumatoid disease are excluded from study.
  • 5Patients who were on treatment with drugs like methotaxate, cyclosporine, theophylline, anticonvulsants like phenytoin, carbamazepine, lipid lowering like cholestyramine, nicotinic acid derivatives (e.g. fenofibrate).

Investigators

Sponsor
All India Institue of Medical sciences AIIMS Rishikesh

Similar Trials